Literature DB >> 15196299

Clinical characteristics of 362 patients with familial migraine with aura.

M K Eriksen1, L L Thomsen, I Andersen, F Nazim, J Olesen.   

Abstract

The objectives of the present study were to describe the clinical characteristics of patients with severe familial non-hemiplegic migraine with aura (NHMA) and to compare these data to those from cases in previous population-based Danish studies using the same methodology. NHMA families were recruited from the Danish patient registry and from Danish neurology practices. A total of 362 NHMA patients were diagnosed according to the 1988 International Headache Society criteria using a validated semistructured physician-conducted interview. Visual aura occurred in almost every NHMA attack. In aura without headache visual aura occurred primarily in isolation. Aura without headache was most common in older, male patients. Several clinical characteristics of familial NHMA differed from migraine with aura in the general population: firstly, the age at onset was lower, secondly, the age at cessation was higher, thirdly, aura symptoms were more severe and finally, the co-occurrence of migraine without aura was higher in familial NHMA. There seems to be a correlation between more severe symptoms and familial aggregation. These results have both clinical and scientific implications.

Entities:  

Mesh:

Year:  2004        PMID: 15196299     DOI: 10.1111/j.1468-2982.2003.00718.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  18 in total

1.  Sensitivity and specificity of the new international diagnostic criteria for migraine with aura.

Authors:  M K Eriksen; L L Thomsen; J Olesen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

Review 2.  Animal models of chronic migraine.

Authors:  Robin James Storer; Weera Supronsinchai; Anan Srikiatkhachorn
Journal:  Curr Pain Headache Rep       Date:  2015-01

Review 3.  Visual disturbances and migraine.

Authors:  Charles E Maxner; Jeremy J Moeller
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 4.  Our evolving understanding of migraine with aura.

Authors:  Justin M DeLange; F Michael Cutrer
Journal:  Curr Pain Headache Rep       Date:  2014-10

Review 5.  Cerebral hemodynamics in the different phases of migraine and cluster headache.

Authors:  Jakob M Hansen; Christoph J Schankin
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-31       Impact factor: 6.200

6.  Primary Headache Disorders: Focus on Migraine.

Authors:  Anish Bahra
Journal:  Rev Pain       Date:  2011-12

7.  Genotype-phenotype correlation in migraine without aura focusing on the rs1835740 variant on 8q22.1.

Authors:  Anne Francke Christensen; Han Le; Malene Kirchmann; Jes Olesen
Journal:  J Headache Pain       Date:  2011-10-01       Impact factor: 7.277

Review 8.  Involvement of gap junction channels in the pathophysiology of migraine with aura.

Authors:  Denis Sarrouilhe; Catherine Dejean; Marc Mesnil
Journal:  Front Physiol       Date:  2014-02-25       Impact factor: 4.566

9.  Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC).

Authors:  Simona Sacco; Gabriele S Merki-Feld; Karen Lehrmann Ægidius; Johannes Bitzer; Marianne Canonico; Tobias Kurth; Christian Lampl; Øjvind Lidegaard; E Anne MacGregor; Antoinette MaassenVanDenBrink; Dimos-Dimitrios Mitsikostas; Rossella Elena Nappi; George Ntaios; Per Morten Sandset; Paolo Martelletti
Journal:  J Headache Pain       Date:  2017-10-30       Impact factor: 7.277

10.  Visual evoked potentials in subgroups of migraine with aura patients.

Authors:  Gianluca Coppola; Martina Bracaglia; Davide Di Lenola; Cherubino Di Lorenzo; Mariano Serrao; Vincenzo Parisi; Antonio Di Renzo; Francesco Martelli; Antonello Fadda; Jean Schoenen; Francesco Pierelli
Journal:  J Headache Pain       Date:  2015-11-02       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.